Corrigendum to: Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockade(Blood Pressure, 2016, 25, (93-103), 10.3109/08037051.2015.1116258);Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade

Blood Pressure

Volumn 25, Issue 2, 2016, Pages 93-103

  Weber, Michael A ^a   Mansfield, Traci A ^b   Alessi, Federica ^b   Iqbal, Nayyar ^c   Parikh, Shamik ^c   Ptaszynska, Agata ^b  

^a SUNY Downstate Medical Center   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Blood pressure; dapagliflozin; diabetes; hypertension; sodium glucose cotransporter 2

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; CREATININE; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PLACEBO; POTASSIUM; TRIACYLGLYCEROL; URIC ACID; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; HYPOVOLEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; AGED; BLOOD; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD RHEOLOGY; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ERROR; METABOLISM; PATHOPHYSIOLOGY; SYSTOLE;

ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSIDES; HEART RATE; HEMOGLOBIN A, GLYCOSYLATED; HEMORHEOLOGY; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; SYSTOLE; URIC ACID;

EID: 84958125420     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037051.2016.1177321     Document Type: Erratum

References (31)

1. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care. 2014;37Suppl1:S14-S80.
2. Colosia AD, Palencia R, Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes. 2013;6:327-338.
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
4. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol. 2006;17:S90-S97.
5. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
6. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585.
7. Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43.
8. Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2013;16:159-169.
9. Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37:740-750.
10. Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16:124-136.
11. Nauck MA, del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015-2022.
12. Woo V, Langkilde AM, Sugg J, Parikh SJ. Dapagliflozin, a novel antihyperglycemic agent that promotes urinary glucose excretion, reduces systolic blood pressure in patients with type 2 diabetes mellitus. Circulation. 2011;124:A9520.
13. Woo V, Leiter LA, Cefalu WT, et al. Blood pressure reduction with dapagliflozin in patients with type 2 diabetes and cardiovascular disease. Circulation. 2013;128:A10606.
14. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.
15. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32:3-15.
16. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697-716.
17. O'Brien E, Mee F, Atkins N, O'Malley K. Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society protocol. J Hypertens. 1991;9:573-574.
18. Vollmer WM, Appel LJ, Svetkey LP, et al. Comparing office-based and ambulatory blood pressure monitoring in clinical trials. J Hum Hypertens. 2005;19:77-82.
19. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020-1031.
20. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217-2224.
21. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8:330-339.
22. Lambers Heerspink HJ, de Zeeuw D, Wie L, et al. Dapagliflozin: a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853-862.
23. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265:3255-264.
24. Malyszko J, Muntner P, Rysz J, Banach M. Blood pressure levels and stroke: J-curve phenomenon? Curr Hypertens Rep. 2013;15:575-581.
25. Weiss RJ, Stapff M, Lin Y. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial. Am J Cardiovasc Drugs. 2013;13:129-140.
26. Sjöström CD, Hashemi M, Sugg J, et al. Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels. Diabetes Obes Metab. 2015;17:809-812.
27. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811-1821.
28. Musini VM, Nazer M, Bassett K, Wright JM. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;5:CD003824.
29. Miao Y, Ottenbros SA, Laverman GD, et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011;58:2-7.
30. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015. [Epub ahead of print].
31. Cefalu WT, Leiter LA, de Bruin TW, et al. Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care. 2015;38:1218-1227.